A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease

被引:227
|
作者
Van Der Auwera I. [1 ]
Wera S. [1 ]
Van Leuven F. [2 ]
Henderson S.T. [3 ]
机构
[1] NV reMYND, 3000 Leuven
[2] Experimental Genetics Group, K.U. Leuven - Campus Gasthuisberg, O and N-06.602
[3] Accera, Inc., Broomfield, CO 80021, 10901 W 120th Ave.
关键词
Caloric Restriction; Amyloid Precursor Protein; Ketone Body; Ketogenic Diet; Object Recognition Test;
D O I
10.1186/1743-7075-2-28
中图分类号
学科分类号
摘要
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder that primarily strikes the elderly. Studies in both humans and animal models have linked the consumption of cholesterol and saturated fats with amyloid-β (Aβ) deposition and development of AD. Yet, these studies did not examine high fat diets in combination with reduced carbohydrate intake. Here we tested the effect of a high saturated fat/low carbohydrate diet on a transgenic mouse model of AD. Results: Starting at three months of age, two groups of female transgenic mice carrying the "London" APP mutation (APP/V7171) were fed either, a standard diet (SD) composed of high carbohydrate/low fat chow, or a ketogenic diet (KD) composed of very low carbohydrate/high saturated fat chow for 43 days. Animals fed the KD exhibited greatly elevated serum ketone body levels, as measured by β-hydroxybutyrate (3.85 ± 2.6 mM), compared to SD fed animals (0.29 ± 0.06 mM). In addition, animals fed the KD lost body weight (SD 22.2 ± 0.6 g vs. KD 17.5 ± 1.4 g, p = 0.0067). In contrast to earlier studies, the brief KD feeding regime significantly reduced total brain Aβ levels by approximately 25%. Despite changes in ketone levels, body weight, and Aβ levels, the KD diet did not alter behavioral measures. Conclusion: Previous studies have suggested that diets rich in cholesterol and saturated fats increased the deposition of Aβ and the risk of developing AD. Here we demonstrate that a diet rich in saturated fats and low in carbohydrates can actually reduce levels of Aβ. Therefore, dietary strategies aimed at reducing Aβ levels should take into account interactions of dietary components and the metabolic outcomes, in particular, levels of carbohydrates, total calories, and presence of ketone bodies should be considered. © 2005 Van der Auwera et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [41] Genetic loci modulating amyloid-beta levels in a mouse model of Alzheimer's disease
    Ryman, Davis
    Gao, Yuan
    Lamb, Bruce T.
    NEUROBIOLOGY OF AGING, 2008, 29 (08) : 1190 - 1198
  • [42] Rocking during sleep reduces motor deficits and beta-amyloid levels in an Alzheimer's mouse model
    Zhang, Luyan
    Santoni, Letizia
    Ngo, Nam Anh
    Simayi, Reyila
    Ficiara, Eleonora
    de Vivo, Luisa
    Bellesi, Michele
    ISCIENCE, 2025, 28 (03)
  • [43] Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease
    Lewczuk, Piotr
    Matzen, Anja
    Blennow, Kaj
    Parnetti, Lucilla
    Molinuevo, Jose Luis
    Eusebi, Paolo
    Kornhuber, Johannes
    Morris, John C.
    Fagan, Anne M.
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 55 (02) : 813 - 822
  • [44] Sargassum fusiforme improves memory and reduces amyloid plaque pathology in an Alzheimer's disease mouse model
    Bogie, J.
    Hoeks, C.
    Schepers, M.
    Tiane, A.
    Cuypers, A.
    Leijten, F.
    Chintapakorn, Y.
    Suttyut, T.
    Pornpakakul, S.
    Struik, D.
    Kerksiek, A.
    Liu, H.
    Hellings, N.
    Martinez-Marinez, P.
    Jonker, J.
    Dewachter, I.
    Sijbrands, E.
    Walter, J.
    Hendriks, J.
    Groen, A.
    Staels, B.
    Luetjohann, D.
    Mulder, M.
    Vanmierlo, T.
    GLIA, 2019, 67 : E430 - E430
  • [45] Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease
    Holtzman, DM
    Bales, KR
    Wu, S
    Bhat, P
    Parsadanian, M
    Fagan, AM
    Chang, LK
    Sun, YL
    Paul, SM
    JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06): : R15 - R21
  • [46] Memantine reduces amyloid and tau pathologies in a triple-transgenic mouse model of Alzheimer's disease
    Martinez-Coria, H.
    Green, K. N.
    Banerjee, P.
    Gupta, S.
    LaFerla, F. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 32 - 32
  • [47] A PPARdelta Agonist Reduces Amyloid Burden and Brain Inflammation in a Transgenic Mouse Model of Alzheimer's Disease
    Kalinin, Sergey
    Richardson, Jill C.
    Feinstein, Douglas L.
    CURRENT ALZHEIMER RESEARCH, 2009, 6 (05) : 431 - 437
  • [48] A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease
    Refolo, LM
    Pappolla, MA
    LaFrancois, J
    Malester, B
    Schmidt, SD
    Thomas-Bryant, T
    Tint, GS
    Wang, R
    Mercken, M
    Petanceska, SS
    Duff, KE
    NEUROBIOLOGY OF DISEASE, 2001, 8 (05) : 890 - 899
  • [49] Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides
    Tobias Hartmann
    Sophie C. Bieger
    Babara Brühl
    Pentti J. Tienari
    Nobuo Ida
    David Allsop
    Gareth W. Roberts
    Colin L. Masters
    Carlos G. Dotti
    Klaus Unsicker
    Konrad Beyreuther
    Nature Medicine, 1997, 3 : 1016 - 1020
  • [50] A nonhuman primate model of Alzheimer’s disease generated by intracranial injection of amyloid-beta42 and thiorphan
    Wende Li
    Yu’e Wu
    Fangui Min
    Zhuo Li
    Jiayuan Huang
    Ren Huang
    Metabolic Brain Disease, 2010, 25 : 277 - 284